JP MORGAN/PUT/BOSTON SCIENTIFIC/45/0.1/17.01.25 | Delayed Börse Stuttgart 03:18:03 2024-06-19 EDT | ||
| 0.07 EUR | -6.67% |
|
| Current month | -3.85% | ||
| 1 month | -7.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 0.07 | -6.67% |
| 24-06-18 | 0.075 | +10.29% |
| 24-06-17 | 0.068 | -8.11% |
| 24-06-14 | 0.074 | +4.23% |
| 24-06-13 | 0.071 | +14.52% |
Delayed Quote Börse Stuttgart
Last update June 19, 2024 at 03:18 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JL03GT |
| ISIN | DE000JL03GT4 |
| Date issued | 2023-04-05 |
| Strike | 45 $ |
| Maturity | 2025-01-17 (213 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.61 € |
|---|---|
| Lowest since issue | 0.058 € |
| Spread | 0.1 € |
| Spread % | 58.82% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
76.31
USD
Average target price
82
USD
Spread / Average Target
+7.45%
- Stock Market
- Warrants
- Warrant
